65LAB, a unique partnership of global investors ClavystBio, Leaps by Bayer, Lightstone Ventures, Polaris Partners and the Polaris Innovation Fund alongside Evotec, has funded
Recipient Professor Enrico Petretto from Duke-NUS is spearheading groundbreaking research to develop new drugs for lung disease and uncover new therapeutic targets for kidney
Recipient Associate Professor Lena Ho spearheads groundbreaking research to develop first-in-class therapeutics to target inflammatory diseases Collaboration between 65LAB and Duke-NUS aims to advance
Read about the key role of 65LAB in Singapore’s burgeoning ecosystem, as it seeks to advance academic projects through the steps towards company formation.
Discover more about the way-markers for a successful translational roadmap from the investor’s perspective Discover more from Evotec
Read DDW’s insights into whether AI can deliver better immunotherapies for cancer, and predictions on what to expect from the sector in 2024 Read
A unique company creation vehicle initiated by Lightstone Ventures and Evotec SE, and established with partners ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund
65LAB partners Thomas Hanke (EVP, Head of Academic Partnerships, Evotec), Christina Isacson (Partner, Lightstone Ventures), and Koh Shuwen (Director, Innovation Transfer Office, National University of Singapore) discuss what it takes to foster venture creation and build global biotech companies.
79 Science Park Drive
Cintech IV, #04-05
Singapore 118264
2023 © Copyright of 65LAB